Index RUT
P/E -
EPS (ttm) -0.74
Insider Own 1.52%
Shs Outstand 76.81M
Perf Week 5.80%
Market Cap 2.68B
Forward P/E 85.08
EPS next Y 0.41
Insider Trans -7.95%
Shs Float 75.65M
Perf Month 10.12%
Income -54.04M
PEG -
EPS next Q 0.04
Inst Own 103.38%
Short Float 3.87%
Perf Quarter 54.53%
Sales 399.58M
P/S 6.70
EPS this Y 122.13%
Inst Trans 0.34%
Short Ratio 3.05
Perf Half Y 61.47%
Book/sh 14.76
P/B 2.36
EPS next Y 81.34%
ROA -4.51%
Short Interest 2.93M
Perf Year 49.29%
Cash/sh 3.07
P/C 11.34
EPS next 5Y -
ROE -4.88%
52W Range 18.61 - 35.51
Perf YTD 26.61%
Dividend Est. -
P/FCF 66.67
EPS past 5Y -10.52%
ROI -4.72%
52W High -1.91%
Beta 1.66
Dividend TTM -
Quick Ratio 4.17
Sales past 5Y 34.42%
Gross Margin 63.87%
52W Low 87.16%
ATR (14) 1.32
Dividend Ex-Date -
Current Ratio 4.44
EPS Y/Y TTM -84.43%
Oper. Margin 1.86%
RSI (14) 67.46
Volatility 3.75% 3.58%
Employees 815
Debt/Eq 0.02
Sales Y/Y TTM 21.59%
Profit Margin -13.52%
Recom 1.67
Target Price 34.57
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 164.11%
Payout -
Rel Volume 1.53
Prev Close 35.25
Sales Surprise 14.09%
EPS Surprise 526.83%
Sales Q/Q 26.69%
Earnings Aug 06 AMC
Avg Volume 959.55K
Price 34.83
SMA20 10.55%
SMA50 23.25%
SMA200 42.39%
Trades
Volume 1,467,292
Change -1.19%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Reiterated
Needham
Buy
$30 → $33
Jan-18-23 Downgrade
Raymond James
Outperform → Mkt Perform
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$33
Jan-07-22 Initiated
Stephens
Overweight
$52
Nov-18-21 Resumed
Goldman
Buy
$60
Jun-15-21 Initiated
Raymond James
Outperform
$45
Feb-18-21 Resumed
Needham
Buy
$88
Jan-28-21 Initiated
Truist
Buy
$61
Nov-10-20 Initiated
KeyBanc Capital Markets
Sector Weight
$48
Sep-09-20 Initiated
Morgan Stanley
Underweight
$35
Jul-31-19 Initiated
Lake Street
Buy
$35
Jul-02-19 Initiated
Needham
Buy
$33
Nov-29-18 Downgrade
Janney
Buy → Neutral
Oct-31-18 Upgrade
Janney
Neutral → Buy
Nov-07-17 Downgrade
Piper Jaffray
Overweight → Neutral
Nov-07-17 Downgrade
Janney
Buy → Neutral
Aug-31-17 Resumed
BTIG Research
Buy
$13
Nov-14-16 Resumed
Leerink Partners
Outperform
$12
Dec-18-15 Initiated
Cantor Fitzgerald
Buy
$13
Jun-11-15 Reiterated
Leerink Partners
Outperform
$11 → $13
Show Previous Ratings
Sep-15-24 08:45AM
Sep-06-24 07:01PM
Sep-05-24 11:31AM
Sep-04-24 04:05PM
09:50AM
05:30PM
Loading…
Aug-26-24 05:30PM
09:00AM
04:36AM
Aug-19-24 09:55AM
Aug-15-24 09:50AM
Aug-14-24 09:15AM
Aug-09-24 07:22PM
Aug-08-24 09:09AM
Aug-07-24 02:08PM
Aug-06-24 06:25PM
05:24PM
Loading…
05:24PM
(Associated Press Finance)
04:05PM
Jul-24-24 10:57AM
Jul-19-24 12:01AM
Jul-17-24 05:00PM
04:48AM
Jun-21-24 09:55AM
Jun-06-24 11:31AM
Jun-03-24 04:05PM
May-29-24 09:55AM
09:30AM
May-28-24 09:31AM
08:47AM
08:32AM
May-23-24 10:00AM
04:05PM
Loading…
May-22-24 04:05PM
May-21-24 09:59AM
May-15-24 05:04PM
May-13-24 09:55AM
May-08-24 03:13PM
08:55AM
07:12AM
(Thomson Reuters StreetEvents)
03:48AM
May-07-24 10:55PM
06:13PM
(Associated Press Finance)
06:00PM
04:05PM
May-06-24 04:05PM
Apr-22-24 05:00PM
08:30AM
Apr-16-24 08:30AM
Apr-02-24 10:33AM
Feb-27-24 05:55PM
Feb-26-24 03:20PM
Feb-23-24 11:10AM
07:43AM
07:37AM
(Thomson Reuters StreetEvents)
Feb-22-24 06:05PM
05:03PM
(Associated Press Finance)
04:40PM
04:05PM
Feb-21-24 05:00PM
Feb-08-24 08:00AM
Feb-06-24 08:15AM
Jan-08-24 08:00AM
Dec-12-23 04:30PM
Dec-01-23 04:05PM
Nov-29-23 08:30AM
Nov-22-23 08:30AM
Nov-08-23 04:39PM
Nov-07-23 04:57PM
(Associated Press Finance)
04:05PM
04:00PM
Nov-02-23 08:15AM
Oct-27-23 08:30AM
Oct-26-23 02:50PM
Oct-17-23 08:15AM
Oct-16-23 10:43AM
Oct-12-23 09:00AM
Oct-04-23 04:05PM
Sep-28-23 04:05PM
08:15AM
Sep-27-23 09:00AM
Sep-21-23 04:05PM
Sep-07-23 04:05PM
Sep-06-23 08:15AM
Sep-02-23 06:15AM
Aug-29-23 08:15AM
Aug-22-23 08:15AM
Aug-15-23 04:15PM
Aug-08-23 06:05PM
04:55PM
04:05PM
Aug-01-23 08:15AM
Jul-19-23 05:00PM
Jul-08-23 08:43PM
Jun-20-23 08:31AM
Jun-12-23 08:31AM
May-30-23 06:56AM
May-25-23 05:13PM
May-24-23 09:00AM
May-23-23 05:00PM
May-22-23 07:30AM
May-12-23 06:15AM
May-05-23 01:59PM
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Leite John Chief Commercial Officer-CLIA Sep 04 '24 Sale 29.78 5,479 163,159 76,174 Sep 06 04:18 PM JOHN LEITE Officer Sep 04 '24 Proposed Sale 30.29 5,479 165,959 Sep 04 04:17 PM JONES EVAN/ FA Director Aug 13 '24 Option Exercise 10.41 8,486 88,339 54,800 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 13 '24 Sale 32.20 27,188 875,565 5,173 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 13 '24 Sale 32.20 20,457 658,801 34,343 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 12 '24 Sale 30.00 101 3,031 32,361 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 12 '24 Sale 30.01 99 2,971 46,314 Aug 14 05:09 PM JONES EVAN/ FA Director Aug 09 '24 Option Exercise 10.41 300 3,123 47,445 Aug 13 04:38 PM JONES EVAN/ FA Director Aug 09 '24 Sale 30.03 1,032 30,990 46,413 Aug 13 04:38 PM JONES EVAN/ FA Director Aug 09 '24 Sale 30.03 746 22,402 32,462 Aug 13 04:38 PM Holstein Jens Director Aug 07 '24 Sale 29.00 5,000 145,000 27,878 Aug 09 04:47 PM JONES EVAN/ FA Director Aug 07 '24 Option Exercise 10.41 1,214 12,638 50,288 Aug 09 04:47 PM JONES EVAN/ FA Director Aug 07 '24 Sale 30.32 5,108 154,883 45,180 Aug 09 04:47 PM Evan Jones Director Aug 07 '24 Proposed Sale 27.05 59,904 1,620,403 Aug 07 07:52 PM EASTHAM KARIN Director Jul 16 '24 Sale 25.00 7,500 187,500 33,228 Jul 18 06:25 PM Leite John Chief Commercial Officer-CLIA Jul 16 '24 Sale 25.00 1,277 31,925 82,968 Jul 18 06:25 PM Holstein Jens Director Jul 16 '24 Sale 24.50 5,000 122,500 32,878 Jul 18 06:25 PM EASTHAM KARIN Director Jun 11 '24 Sale 20.59 3,870 79,683 29,255 Jun 13 04:24 PM Bhanji Muna Director Jun 10 '24 Sale 20.32 3,870 78,634 23,105 Jun 11 04:22 PM EASTHAM KARIN Director Jun 07 '24 Option Exercise 10.41 2,500 26,025 35,625 Jun 11 04:21 PM EASTHAM KARIN Director Jun 07 '24 Sale 20.97 2,500 52,425 33,125 Jun 11 04:21 PM Bhanji Muna Director May 28 '24 Sale 21.00 1,539 32,319 26,975 May 30 04:41 PM EASTHAM KARIN Director Apr 01 '24 Option Exercise 13.19 10,000 131,900 43,125 Apr 02 04:17 PM EASTHAM KARIN Director Apr 01 '24 Sale 21.65 10,000 216,528 33,125 Apr 02 04:17 PM JONES EVAN/ FA Director Mar 01 '24 Option Exercise 13.19 10,000 131,900 47,601 Mar 05 05:28 PM JONES EVAN/ FA Director Mar 01 '24 Sale 24.36 10,000 243,599 37,601 Mar 05 05:28 PM
Index RUT
P/E -
EPS (ttm) -5.37
Insider Own 3.33%
Shs Outstand 117.66M
Perf Week -3.78%
Market Cap 6.33B
Forward P/E -
EPS next Y -4.86
Insider Trans -6.57%
Shs Float 113.74M
Perf Month -4.97%
Income -545.28M
PEG -
EPS next Q -1.24
Inst Own 113.90%
Short Float 16.01%
Perf Quarter 0.47%
Sales 3.13M
P/S 2021.27
EPS this Y 6.02%
Inst Trans -1.19%
Short Ratio 12.76
Perf Half Y -18.57%
Book/sh 0.92
P/B 58.22
EPS next Y 5.10%
ROA -47.34%
Short Interest 18.21M
Perf Year 68.19%
Cash/sh 8.98
P/C 5.98
EPS next 5Y 15.00%
ROE -
52W Range 25.98 - 110.25
Perf YTD -35.60%
Dividend Est. -
P/FCF -
EPS past 5Y -22.79%
ROI -62.77%
52W High -51.23%
Beta 0.78
Dividend TTM -
Quick Ratio 10.39
Sales past 5Y 12.30%
Gross Margin -312.44%
52W Low 106.97%
ATR (14) 2.41
Dividend Ex-Date -
Current Ratio 10.39
EPS Y/Y TTM 5.62%
Oper. Margin -16148.37%
RSI (14) 42.82
Volatility 5.56% 4.20%
Employees 423
Debt/Eq 7.28
Sales Y/Y TTM -68.51%
Profit Margin -17398.82%
Recom 1.56
Target Price 79.75
Option/Short Yes / Yes
LT Debt/Eq 7.00
EPS Q/Q 2.34%
Payout -
Rel Volume 2.23
Prev Close 55.60
Sales Surprise -96.73%
EPS Surprise -23.98%
Sales Q/Q -71.28%
Earnings Aug 08 AMC
Avg Volume 1.43M
Price 53.77
SMA20 -3.47%
SMA50 -4.40%
SMA200 -14.40%
Trades
Volume 3,186,355
Change -3.29%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-24 Downgrade
Goldman
Buy → Neutral
$85 → $60
Jan-24-24 Downgrade
UBS
Buy → Neutral
$61 → $92
Jan-05-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$60 → $90
Nov-09-23 Initiated
Goldman
Buy
$50
Nov-07-23 Initiated
B. Riley Securities
Buy
$66
Aug-15-23 Initiated
SVB Securities
Outperform
$58
Feb-17-23 Initiated
BofA Securities
Neutral
$49
Dec-23-22 Reiterated
Needham
Buy
$60 → $58
Dec-20-22 Initiated
Truist
Buy
$60
Oct-11-22 Initiated
UBS
Buy
$80
Jan-28-22 Initiated
Goldman
Buy
$74
Dec-22-21 Initiated
Oppenheimer
Outperform
$55
Dec-10-21 Initiated
JP Morgan
Overweight
$58
Oct-07-21 Initiated
Jefferies
Buy
$75
Mar-12-21 Initiated
Wolfe Research
Outperform
$50
Feb-18-21 Initiated
Barclays
Overweight
$28
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$22 → $41
Oct-29-20 Initiated
Goldman
Neutral
$16
Jul-10-20 Initiated
Raymond James
Strong Buy
$39
May-05-20 Initiated
Mizuho
Buy
$31
Show Previous Ratings
Sep-19-24 04:08PM
(Investor's Business Daily)
04:00PM
09:22AM
(Investor's Business Daily)
Sep-09-24 01:11PM
07:30AM
01:55AM
Loading…
Sep-08-24 01:55AM
Sep-05-24 04:00PM
Sep-04-24 04:00PM
01:16AM
Sep-01-24 04:27AM
03:51AM
Aug-29-24 04:00PM
Aug-22-24 07:01PM
Aug-09-24 10:20AM
Aug-08-24 09:59PM
05:10PM
Loading…
05:10PM
04:13PM
(Associated Press Finance)
04:00PM
01:01AM
Aug-01-24 04:00PM
Jul-30-24 07:30AM
Jul-25-24 04:00PM
10:01AM
Jul-23-24 07:01PM
Jul-17-24 08:00AM
Jul-16-24 07:30AM
Jul-11-24 08:00AM
(Investor's Business Daily)
08:00AM
(Investor's Business Daily)
Jul-10-24 01:42AM
Jul-03-24 04:00PM
02:46AM
Loading…
Jul-02-24 02:46AM
Jun-26-24 02:11PM
Jun-18-24 01:49AM
Jun-17-24 07:30AM
Jun-12-24 02:37AM
Jun-10-24 07:00PM
Jun-05-24 07:55AM
06:14AM
03:00AM
Jun-04-24 04:00PM
02:38AM
May-29-24 04:00PM
May-28-24 04:00PM
May-27-24 06:28PM
06:13PM
May-24-24 11:12AM
May-23-24 09:40AM
(FierceBiotech.com) -17.31%
07:50AM
May-22-24 11:30PM
04:10PM
04:02PM
04:00PM
May-17-24 07:30AM
May-15-24 07:30AM
May-14-24 04:01PM
(Investor's Business Daily)
May-13-24 05:24PM
(The Wall Street Journal) -6.78%
04:08PM
(Investor's Business Daily)
09:43AM
(Investor's Business Daily)
09:33AM
09:33AM
09:11AM
May-10-24 12:37PM
May-09-24 10:48AM
10:46AM
07:01AM
May-08-24 09:00PM
05:18PM
05:10PM
04:06PM
(Associated Press Finance)
04:00PM
07:30AM
07:30AM
02:23AM
May-07-24 05:02PM
04:00PM
02:04PM
May-02-24 04:00PM
May-01-24 10:01AM
Apr-29-24 04:00PM
Apr-26-24 04:44PM
06:00AM
Apr-24-24 04:00PM
Apr-10-24 09:27AM
07:30AM
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-13-24 02:25PM
Mar-12-24 06:46AM
(Thomson Reuters StreetEvents)
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
(FierceBiotech.com) -9.75%
10:22AM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Malik Fady Ibraham EVP Research & Development Sep 17 '24 Option Exercise 7.96 5,300 42,188 128,220 Sep 17 04:15 PM Malik Fady Ibraham EVP Research & Development Sep 17 '24 Sale 56.77 7,300 414,401 120,920 Sep 17 04:15 PM Blum Robert I President & CEO Sep 16 '24 Option Exercise 6.67 5,000 33,350 402,456 Sep 17 04:10 PM Blum Robert I President & CEO Sep 16 '24 Sale 55.99 5,000 279,950 397,456 Sep 17 04:10 PM FADY MALIK Officer Sep 17 '24 Proposed Sale 56.77 7,300 414,401 Sep 17 04:03 PM ROBERT BLUM Officer Sep 16 '24 Proposed Sale 55.99 5,000 279,962 Sep 16 04:29 PM B LYNNE PARSHALL Director Sep 09 '24 Proposed Sale 54.92 5,000 274,582 Sep 09 04:12 PM PARSHALL B LYNNE Director Sep 09 '24 Option Exercise 21.61 5,000 108,050 25,600 Sep 09 04:05 PM PARSHALL B LYNNE Director Sep 09 '24 Sale 54.92 5,000 274,600 20,600 Sep 09 04:05 PM Malik Fady Ibraham EVP Research & Development Sep 03 '24 Option Exercise 7.96 5,300 42,188 128,220 Sep 03 05:14 PM Malik Fady Ibraham EVP Research & Development Sep 03 '24 Sale 57.01 7,384 420,973 122,920 Sep 03 05:14 PM Blum Robert I President & CEO Sep 03 '24 Option Exercise 6.67 5,000 33,350 402,456 Sep 03 05:09 PM Blum Robert I President & CEO Sep 03 '24 Sale 57.03 5,000 285,150 397,456 Sep 03 05:09 PM ROBERT BLUM Officer Sep 03 '24 Proposed Sale 57.03 5,000 285,126 Sep 03 04:08 PM FADY MALIK Officer Sep 03 '24 Proposed Sale 57.01 7,384 420,973 Sep 03 04:07 PM B LYNNE PARSHALL Director Aug 26 '24 Proposed Sale 57.26 5,000 286,288 Aug 26 04:14 PM PARSHALL B LYNNE Director Aug 26 '24 Option Exercise 21.61 5,000 108,050 25,600 Aug 26 04:00 PM PARSHALL B LYNNE Director Aug 26 '24 Sale 57.26 5,000 286,300 20,600 Aug 26 04:00 PM Malik Fady Ibraham EVP Research & Development Aug 20 '24 Option Exercise 7.96 5,300 42,188 130,304 Aug 22 04:00 PM Malik Fady Ibraham EVP Research & Development Aug 20 '24 Sale 56.25 7,300 410,638 125,004 Aug 22 04:00 PM FADY MALIK Officer Aug 20 '24 Proposed Sale 56.26 7,300 410,669 Aug 20 04:08 PM Blum Robert I President & CEO Aug 12 '24 Option Exercise 6.67 11,500 76,705 410,912 Aug 12 05:32 PM Blum Robert I President & CEO Aug 12 '24 Sale 55.17 11,500 634,455 399,412 Aug 12 05:32 PM PARSHALL B LYNNE Director Aug 12 '24 Option Exercise 21.61 5,000 108,050 25,600 Aug 12 05:31 PM PARSHALL B LYNNE Director Aug 12 '24 Sale 55.20 5,000 276,000 20,600 Aug 12 05:31 PM B LYNNE PARSHALL Director Aug 12 '24 Proposed Sale 55.20 5,000 276,007 Aug 12 04:24 PM ROBERT BLUM Officer Aug 12 '24 Proposed Sale 55.17 11,500 634,470 Aug 12 04:21 PM Malik Fady Ibraham EVP Research & Development Aug 07 '24 Option Exercise 7.96 5,300 42,188 127,004 Aug 07 08:06 PM Malik Fady Ibraham EVP Research & Development Aug 06 '24 Sale 53.71 7,300 392,090 121,704 Aug 07 08:06 PM FADY MALIK Officer Aug 06 '24 Proposed Sale 53.71 7,300 392,096 Aug 06 04:14 PM PARSHALL B LYNNE Director Jul 29 '24 Option Exercise 21.61 5,000 108,050 25,600 Jul 31 04:39 PM PARSHALL B LYNNE Director Jul 29 '24 Sale 59.84 5,000 299,200 20,600 Jul 31 04:39 PM Blum Robert I President & CEO Jul 30 '24 Option Exercise 6.67 11,500 76,705 410,912 Jul 31 04:36 PM Blum Robert I President & CEO Jul 30 '24 Sale 59.49 11,500 684,135 399,412 Jul 31 04:36 PM ROBERT BLUM Officer Jul 30 '24 Proposed Sale 59.49 11,500 684,158 Jul 30 04:13 PM B LYNNE PARSHALL Director Jul 29 '24 Proposed Sale 59.84 5,000 299,217 Jul 29 04:17 PM Malik Fady Ibraham EVP Research & Development Jul 23 '24 Option Exercise 7.96 5,300 42,188 134,304 Jul 23 04:47 PM Malik Fady Ibraham EVP Research & Development Jul 23 '24 Sale 57.02 7,300 416,246 129,004 Jul 23 04:47 PM PARSHALL B LYNNE Director Jul 15 '24 Option Exercise 10.68 5,000 53,400 25,600 Jul 16 05:05 PM PARSHALL B LYNNE Director Jul 15 '24 Sale 55.82 5,000 279,100 20,600 Jul 16 05:05 PM Blum Robert I President & CEO Jul 10 '24 Option Exercise 6.67 5,767 38,466 410,912 Jul 10 05:24 PM Blum Robert I President & CEO Jul 10 '24 Sale 54.29 11,500 624,335 399,412 Jul 10 05:24 PM Malik Fady Ibraham EVP Research & Development Jul 09 '24 Option Exercise 7.96 5,300 42,188 138,304 Jul 09 06:15 PM Malik Fady Ibraham EVP Research & Development Jul 09 '24 Sale 55.90 7,300 408,103 131,004 Jul 09 06:15 PM Harrington Robert Arthur Director Jul 05 '24 Sale 54.61 253 13,816 15,516 Jul 08 05:06 PM PARSHALL B LYNNE Director Jul 01 '24 Option Exercise 10.68 5,000 53,400 25,600 Jul 01 05:12 PM PARSHALL B LYNNE Director Jul 01 '24 Sale 54.22 5,000 271,100 20,600 Jul 01 05:12 PM Blum Robert I President & CEO Jul 01 '24 Sale 54.05 11,500 621,575 405,145 Jul 01 05:04 PM Malik Fady Ibraham EVP Research & Development Jun 25 '24 Option Exercise 7.96 5,300 42,188 138,304 Jun 25 08:04 PM Malik Fady Ibraham EVP Research & Development Jun 25 '24 Sale 53.72 7,300 392,143 133,004 Jun 25 08:04 PM PARSHALL B LYNNE Director Jun 17 '24 Option Exercise 10.68 5,000 53,400 25,600 Jun 17 05:17 PM PARSHALL B LYNNE Director Jun 17 '24 Sale 52.55 5,000 262,750 20,600 Jun 17 05:17 PM Blum Robert I President & CEO Jun 17 '24 Sale 52.60 22,500 1,183,391 416,645 Jun 17 05:13 PM Malik Fady Ibraham EVP Research & Development Jun 11 '24 Option Exercise 7.96 5,422 43,159 142,792 Jun 11 04:22 PM Malik Fady Ibraham EVP Research & Development Jun 11 '24 Sale 53.04 7,788 413,106 135,004 Jun 11 04:22 PM Bhanji Muna Director Jun 10 '24 Sale 52.07 2,000 104,140 17,631 Jun 10 04:15 PM Blum Robert I President & CEO Jun 04 '24 Sale 48.85 22,500 1,099,125 439,145 Jun 07 04:03 PM Harrington Robert Arthur Director Jun 03 '24 Sale 48.64 1,580 76,851 15,541 Jun 05 05:23 PM PARSHALL B LYNNE Director Jun 03 '24 Option Exercise 10.68 5,000 53,400 20,600 Jun 04 04:30 PM PARSHALL B LYNNE Director Jun 03 '24 Sale 48.64 5,000 243,200 15,600 Jun 04 04:30 PM Wong Robert VP, Chief Accounting Officer Jun 03 '24 Sale 48.88 13,011 635,978 16,653 Jun 03 04:33 PM Malik Fady Ibraham EVP Research & Development May 07 '24 Option Exercise 6.67 14,186 94,621 152,603 May 07 04:37 PM Malik Fady Ibraham EVP Research & Development May 07 '24 Sale 65.11 15,547 1,012,265 137,056 May 07 04:37 PM HENDERSON JOHN T Director Apr 25 '24 Sale 64.54 10,562 681,671 32,070 Apr 25 06:54 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Option Exercise 6.67 28,605 190,795 171,172 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Sale 74.31 32,605 2,422,918 138,567 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Option Exercise 6.67 28,604 190,789 167,577 Mar 05 04:05 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Sale 67.56 32,604 2,202,606 138,973 Mar 05 04:05 PM HENDERSON JOHN T Director Feb 14 '24 Option Exercise 4.44 5,000 22,200 47,632 Feb 14 04:04 PM HENDERSON JOHN T Director Feb 14 '24 Sale 76.48 5,000 382,400 42,632 Feb 14 04:04 PM Blum Robert I President & CEO Feb 13 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 13 04:01 PM Blum Robert I President & CEO Feb 13 '24 Sale 76.85 12,500 960,625 441,797 Feb 13 04:01 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Option Exercise 6.67 28,605 190,795 175,578 Feb 06 04:43 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Sale 79.30 32,605 2,585,496 142,973 Feb 06 04:43 PM Blum Robert I President & CEO Jan 31 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 02 04:41 PM Blum Robert I President & CEO Jan 31 '24 Sale 79.57 12,500 994,625 441,797 Feb 02 04:41 PM Blum Robert I President & CEO Jan 19 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 22 05:19 PM Blum Robert I President & CEO Jan 19 '24 Sale 81.42 12,500 1,017,750 441,797 Jan 22 05:19 PM HENDERSON JOHN T Director Jan 12 '24 Option Exercise 4.44 5,000 22,200 47,632 Jan 12 05:20 PM HENDERSON JOHN T Director Jan 12 '24 Sale 85.14 5,000 425,700 42,632 Jan 12 05:20 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Option Exercise 7.96 11,678 92,957 162,651 Jan 04 04:36 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Sale 86.98 15,678 1,363,712 146,973 Jan 04 04:36 PM Blum Robert I President & CEO Jan 02 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 02 05:55 PM Blum Robert I President & CEO Jan 02 '24 Sale 85.08 12,500 1,063,500 441,797 Jan 02 05:55 PM WIERENGA WENDALL Director Dec 27 '23 Option Exercise 4.44 10,000 44,400 23,653 Dec 27 04:11 PM WIERENGA WENDALL Director Dec 27 '23 Sale 73.60 10,000 736,000 18,653 Dec 27 04:11 PM Blum Robert I President & CEO Dec 18 '23 Option Exercise 6.67 12,500 83,375 454,297 Dec 19 04:13 PM Blum Robert I President & CEO Dec 18 '23 Sale 36.95 12,500 461,875 441,797 Dec 19 04:13 PM HENDERSON JOHN T Director Dec 18 '23 Option Exercise 6.72 13,020 87,494 44,838 Dec 19 04:12 PM HENDERSON JOHN T Director Dec 18 '23 Sale 36.34 2,458 89,324 42,380 Dec 19 04:12 PM Blum Robert I President & CEO Nov 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Dec 01 04:15 PM Blum Robert I President & CEO Nov 30 '23 Sale 32.99 12,500 412,375 441,417 Dec 01 04:15 PM Blum Robert I President & CEO Nov 15 '23 Option Exercise 6.67 12,500 83,375 453,917 Nov 15 05:22 PM Blum Robert I President & CEO Nov 15 '23 Sale 34.57 12,500 432,125 441,417 Nov 15 05:22 PM Malik Fady Ibraham EVP Research & Development Nov 09 '23 Sale 35.40 2,500 88,500 150,664 Nov 09 04:35 PM Blum Robert I President & CEO Oct 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 30 04:02 PM Blum Robert I President & CEO Oct 30 '23 Sale 32.17 12,500 402,125 441,417 Oct 30 04:02 PM Blum Robert I President & CEO Oct 16 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 16 05:57 PM Blum Robert I President & CEO Oct 16 '23 Sale 33.70 12,500 421,250 441,417 Oct 16 05:57 PM Malik Fady Ibraham EVP Research & Development Oct 12 '23 Sale 35.89 2,500 89,725 153,164 Oct 12 06:39 PM
Index RUT
P/E -
EPS (ttm) -5.48
Insider Own 1.77%
Shs Outstand 101.58M
Perf Week -0.86%
Market Cap 2.22B
Forward P/E -
EPS next Y -5.53
Insider Trans -0.11%
Shs Float 99.78M
Perf Month -7.33%
Income -508.80M
PEG -
EPS next Q -1.39
Inst Own 85.92%
Short Float 13.73%
Perf Quarter -9.66%
Sales 45.97M
P/S 48.35
EPS this Y 0.68%
Inst Trans -0.29%
Short Ratio 9.15
Perf Half Y -20.87%
Book/sh 9.88
P/B 2.21
EPS next Y -2.80%
ROA -40.46%
Short Interest 13.70M
Perf Year -35.63%
Cash/sh 6.80
P/C 3.22
EPS next 5Y 30.00%
ROE -49.02%
52W Range 19.21 - 34.94
Perf YTD -28.24%
Dividend Est. -
P/FCF -
EPS past 5Y -22.30%
ROI -48.07%
52W High -37.38%
Beta 1.77
Dividend TTM -
Quick Ratio 7.21
Sales past 5Y 12.09%
Gross Margin 78.53%
52W Low 13.90%
ATR (14) 1.22
Dividend Ex-Date -
Current Ratio 7.21
EPS Y/Y TTM -0.32%
Oper. Margin -1140.05%
RSI (14) 48.46
Volatility 5.05% 5.14%
Employees 526
Debt/Eq 0.11
Sales Y/Y TTM -13.33%
Profit Margin -1106.87%
Recom 1.50
Target Price 67.40
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -8.06%
Payout -
Rel Volume 2.08
Prev Close 22.93
Sales Surprise -64.64%
EPS Surprise -24.92%
Sales Q/Q -48.82%
Earnings Aug 08 BMO
Avg Volume 1.50M
Price 21.88
SMA20 0.16%
SMA50 -6.44%
SMA200 -14.22%
Trades
Volume 3,115,306
Change -4.58%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Downgrade
Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated
Wolfe Research
Peer Perform
Apr-13-23 Initiated
Canaccord Genuity
Buy
$66
Mar-21-23 Initiated
Bernstein
Outperform
$54
Mar-14-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated
Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade
Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated
Morgan Stanley
Overweight
$84
Sep-21-22 Initiated
JP Morgan
Overweight
$85
Sep-01-22 Initiated
Citigroup
Sell
$50
Jun-17-22 Initiated
BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated
BofA Securities
Buy
$70
Apr-28-22 Initiated
Credit Suisse
Outperform
$100
Feb-18-22 Initiated
William Blair
Outperform
$144
Feb-07-22 Upgrade
Oppenheimer
Perform → Outperform
$145 → $150
Jan-31-22 Initiated
Cowen
Outperform
Jan-07-22 Initiated
Piper Sandler
Overweight
$171
Oct-05-21 Initiated
Guggenheim
Buy
$170
Sep-24-21 Initiated
Stifel
Buy
$173
Show Previous Ratings
Sep-12-24 01:01PM
(The Wall Street Journal)
07:30AM
Sep-03-24 04:30PM
Aug-14-24 10:29AM
Aug-09-24 11:32AM
10:19AM
Loading…
10:19AM
Aug-08-24 07:01PM
(Morningstar Research) +5.02%
12:23PM
08:55AM
07:30AM
Aug-06-24 12:48PM
Aug-01-24 11:15AM
07:30AM
Jul-31-24 07:33AM
Jul-30-24 07:30AM
09:58AM
Loading…
Jul-26-24 09:58AM
Jul-24-24 04:01PM
Jul-23-24 02:57PM
Jul-17-24 01:30PM
11:30AM
Jul-11-24 12:00PM
Jul-09-24 07:59AM
07:00AM
05:56AM
Jul-08-24 09:00AM
06:00AM
Jul-05-24 02:14PM
Jul-02-24 08:30AM
Jun-28-24 10:28AM
Jun-27-24 10:02PM
10:38AM
Loading…
10:38AM
Jun-26-24 09:33PM
07:30AM
05:22AM
Jun-25-24 03:30PM
08:00AM
Jun-21-24 06:30AM
Jun-17-24 07:30AM
Jun-14-24 11:49AM
07:30AM
Jun-09-24 06:20AM
Jun-08-24 07:25AM
Jun-07-24 11:25AM
Jun-06-24 11:05AM
Jun-05-24 01:35PM
Jun-04-24 11:21AM
06:45AM
Jun-03-24 04:31PM
04:17PM
Jun-02-24 08:00AM
May-25-24 08:30AM
May-22-24 11:15AM
May-14-24 12:46PM
09:30AM
May-13-24 02:18PM
May-10-24 03:35PM
01:16PM
11:45AM
11:26AM
May-09-24 11:53PM
(Thomson Reuters StreetEvents) +8.09%
11:42AM
08:49AM
08:40AM
07:30AM
May-03-24 06:15PM
02:18PM
May-02-24 07:30AM
06:04AM
Apr-29-24 07:30AM
Apr-25-24 11:21AM
10:01AM
Apr-14-24 05:55AM
Apr-12-24 04:50AM
Apr-09-24 04:50AM
Mar-28-24 05:55AM
Mar-21-24 05:29PM
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
(Thomson Reuters StreetEvents)
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Clark Eliana EVP, Chief Technical Officer Jul 01 '24 Sale 22.93 405 9,287 71,470 Jul 03 01:15 PM Verwiel Frank Director Jun 17 '24 Sale 25.00 1,505 37,625 17,948 Jun 20 05:00 PM BASTA JAMES EVP, General Counsel Mar 04 '24 Sale 32.99 2,297 75,778 81,571 Mar 05 04:10 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '24 Sale 32.99 605 19,959 71,470 Mar 05 04:10 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 08 '24 Sale 28.87 2,275 65,682 43,927 Jan 10 04:15 PM LEONARD JOHN M President and CEO Jan 03 '24 Sale 29.46 19,223 566,310 846,486 Jan 05 04:51 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '24 Sale 29.46 5,843 172,135 54,372 Jan 05 04:50 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '24 Sale 29.46 5,532 162,973 46,202 Jan 05 04:50 PM Goddard Glenn EVP, Chief Financial Officer Jan 03 '24 Sale 29.46 5,365 158,053 40,585 Jan 05 04:49 PM Hicks Derek EVP, Chief Business Officer Jan 03 '24 Sale 29.46 3,877 114,216 36,987 Jan 05 04:46 PM BASTA JAMES EVP, General Counsel Jan 03 '24 Sale 29.46 3,805 112,095 51,474 Jan 05 04:45 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '24 Sale 29.50 4,608 135,954 40,845 Jan 05 04:44 PM Bhanji Muna Director Oct 31 '23 Sale 23.90 265 6,334 11,996 Nov 02 04:42 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite